Evaluating multicenter DTI data in Huntington's disease on site specific effects: An ex post facto approach  by Müller, Hans-Peter et al.
NeuroImage: Clinical 2 (2013) 161–167
Contents lists available at ScienceDirect
NeuroImage: Clinical
j ourna l homepage: www.e lsev ie r .com/ locate /yn ic lEvaluating multicenter DTI data in Huntington's disease on site speciﬁc
effects: An ex post facto approachHans-Peter Müller a,⁎,1, Georg Grön b,1, Reiner Sprengelmeyer a,f, Jan Kassubek a, Albert C. Ludolph a,
Nicola Hobbs c, James Cole c, Raymund A.C. Roos d, Alexandra Duerr e, Sarah J. Tabrizi c,
G. Bernhard Landwehrmeyer a, Sigurd D. Süssmuth a
a Department of Neurology, University of Ulm, Germany
b Section for Neuropsychology and Functional Imaging, Department of Psychiatry, University of Ulm, Germany
c Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
d Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands
e Neuroimaging Centre, CENIR, Paris, France
f School of Psychology and Neuroscience, University of St Andrews, Scotland, UK⁎ Correspondingauthor at:Department of Neurology, Un
45, 89081 Ulm, Germany. Tel.: +49 731 1771206.
E-mail address: hans-peter.mueller@uni-ulm.de (H.-
1 Shared ﬁrst authorship.
2213-1582 © 2013 The Authors. Published by Elsevier I
http://dx.doi.org/10.1016/j.nicl.2012.12.005a b s t r a c ta r t i c l e i n f oArticle history:
Received 24 August 2012
Received in revised form 11 December 2012
Accepted 21 December 2012






Purpose: Assessment of the feasibility to average diffusion tensor imaging (DTI) metrics of MRI data acquired
in the course of a multicenter study.
Materials and methods: Sixty-one early stage Huntington's disease patients and forty healthy controls were
studied using four different MR scanners at four European sites with acquisition protocols as close as possible
to a given standard protocol. The potential and feasibility of averaging data acquired at different sites was
evaluated quantitatively by region-of-interest (ROI) based statistical comparisons of coefﬁcients of variation
(CV) across centers, as well as by testing for signiﬁcant group-by-center differences on averaged fractional
anisotropy (FA) values between patients and controls. In addition, a whole-brain based statistical
between-group comparison was performed using FA maps.
Results: The ex post facto statistical evaluation of CV and FA-values in a priori deﬁned ROIs showed no differ-
ences between sites above chance indicating that data were not systematically biased by center speciﬁc fac-
tors.
Conclusion: Averaging FA-maps from DTI data acquired at different study sites and different MR scanner types
does not appear to be systematically biased. A suitable recipe for testing on the possibility to pool multicenter
DTI data is provided to permit averaging of DTI-derived metrics to differentiate patients from healthy con-
trols at a larger scale.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license. 1. Introduction
In the last decade the necessity for multicenter studies has arisen
in order to increase sample sizes and therefore reliability of results.
This multicenter approach is particularly important for rare disorders,
such as Huntington's disease (HD), because it permits collecting data
from a sufﬁciently large number of participants in a reasonable time
frame.iversity ofUlm,Oberer Eselsberg
P. Müller).
nc. Open access under CC BY-NC-SA licCerebral white matter (WM) changes in HD have been reported in
a number of studies (for reviews see Bohanna et al. (2008) and
Klöppel et al. (2009)), mainly using MR-based diffusion weighted im-
aging (DWI) and diffusion tensor imaging (DTI) (Douaud et al., 2009;
Rosas et al., 2006). These techniques use diffusion directions of water
molecules to calculate a tensor, which can be converted into metrics
such as fractional anisotropy (FA) (Basser and Jones, 2002; Pierpaoli
et al., 1996), a dimensionless scalar ranging from a value of zero
(isotropy) to a value of one (high directionality, anisotropy). There
is, however, a downside to multicenter imaging studies focusing on
DTI, in that scanner and environmental noise, as well as systematic
inter-subject variables may contribute to the variability of DTI results.
Some effort has already been made to investigate the inﬂuence of
these variables on scanning results. Pagani and colleagues demon-
strated between-center differences in DTI repeatedly scanning a
number of subjects (between 7 and 13) at 8 different scanner sites
(Pagani et al., 2010). By contrast, other authors reported only smallense. 
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phantom (Teipel et al., 2011; Walker et al., 2012). Other studies fo-
cused on comparability of DTI metrics from different scanners by re-
gion of interest (ROI) analyses of coefﬁcients of variation (CV). They
found that FA is the most comparable measure across different scan-
ners and that nonlinear co-registration of FA maps reduced average
inter-site CV (Fox et al., 2012; Vollmar et al., 2010).
A common way to reduce variability is to calibrate all scanners in-
volved in a multicenter study, with the optimal procedure being to
scan a number of participants as a reference group at each study cen-
ter. However, this is a time consuming and expensive procedure, and
not viable for many important but underfunded studies. Therefore,
other equally valid ways of ensuring comparability of DTI results
from different scanners should be explored.
As a proof of concept, we used DTI data from early HD and control
participants acquired from four different scanners. For comparison,
we deﬁned ﬁve ROIs based on previous ﬁndings in DTI studies with
HD patients, i.e. basal ganglia, external and internal capsules, thalamic
region and corpus callosum (Douaud et al., 2009; Rosas et al., 2006).
These ﬁve structures have been identiﬁed as being particularlyFig. 1. Different sources of variability may contribute to the diffusion data of control subjects (C
of variation cannot be singled out, the coefﬁcient of variance (CV) from the CO data of each cen
data. Investigating FA group differences between patients and controls on systematic between-
ted. The calibration procedure as well as the inclusion of more subjects is an option and is an aaffected in people with manifest HD with a speciﬁc pattern of de-
creases and increases in FA values. The regions most affected were
the basal ganglia with an increase in FA and the internal and external
capsules and the thalamic regions which showed FA decreases (Rosas
et al., 2006). It should be noted that these studies were not multicen-
ter studies and that all participants were scanned with the same MRI
scanner.
The aim of our study was to provide an evaluating framework for
combining DTI data acquired from different study centers without
time- and cost-intensive repeated scanning of the same reference
group at each study site. As the primary outcome variable the present
study focused on FA data as the relevant DTI metric since FA differ-
ences between HD subjects and controls have already been reported
(Douaud et al., 2009; Fox et al., 2012; Rosas et al., 2006). For analysis,
we suggest a three-step procedure as outlined in Fig. 1. In the ﬁrst
step we tested whether the CV of FA values in predeﬁned ROIs dif-
fered between centers. In this step we used data from control partic-
ipants to estimate potential inﬂuences independent of disease related
factors. In the second step we tested whether group differences be-
tween patients and controls differed between centers. In the thirdO) and patients with Huntington's disease (HD). Although the contribution of each source
ter serves as an estimate whether one or more centers contributed systematically biased
center differences is a further criterion to decidewhether pooling across centers is permit-
lternative if the various checks do not permit pooling the data.
Table 2
Demographic parameters and distribution of patients with Huntington's disease (HD)
and controls (CO) investigated at the 4 different centers (mean±standard deviation).
N of subjects Age (years) Sex (m/f)
CO HD CO HD CO HD
Center A 10 17 50±4 48±10 6/4 3/14
Center B 10 16 53±8 52±9 5/5 5/11
Center C 10 13 57±8 46±15 3/7 7/6
Center D 10 15 48±9 48±10 4/6 11/4
All 40 61 52±8 49±11 18/22 26/35
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and a voxel-wise whole-brain analysis was performed to assess
whether putative group differences were present in the selected
ROIs. This procedure may also help to monitor multi-center (DTI)
studies.
2. Methods
2.1. Data collection and participants
Data in this study were collected as part of the European
PADDINGTON project at four study sites in Europe (Leiden, the
Netherlands; London, UK; Paris, France; Ulm, Germany). The
PADDINGTON project, which involves ﬁve partners (Siena Biotech
SpA, University of Ulm, University College London, the London School
of Hygiene and Tropical Medicine and KCR Poland), is an international
initiative that aims to provide pharmacodynamic approaches for
disease-modifying clinical trials. The work package 2 of this project en-
tails the collection of volumetric 3 Tesla MRI and DTI scans acquired
with standardized acquisition protocols from patients with HD in an
early disease stage and from healthy control participants, with the ob-
jective of identifying biomarkers of disease progression. DTI data from
work package 2 were used to evaluate our three-step procedure.
All participants gave written informed consent. Subjects were at
least 18 years old. HD patients had a genetically conﬁrmed diagnosis
with a trinucleotide (CAG) repeat length of 36 or higher, and had clin-
ical features of mild HD at least of stage I based on the Uniﬁed
Huntington's Disease Rating Scale (UHDRS) with a total functional
capacity (TFC) score of 11–13. All participants were ambulatory and
agreed to volunteer for MRI scanning. Subjects with claustrophobia
and conditions not permitting MR scanning were excluded from the
study. In total 61 HD and 40 control subjects (CO) were scanned
(DTI acquisition time is approximately 7 min per subject). The acquisi-
tion parameters for the different sites are listed in Table 1, and sample
sizes are listed in Table 2.
2.2. Data analysis — post-processing
The in-house developed DTI analysis software Tensor Imaging and
Fibre Tracking (TIFT; Müller et al., 2007a, 2007b) with additional
routines for eddy current correction was used for post-processing
and statistical analysis. Prior to FA-calculation motion artifacts were
eliminated in each volume and each subject separately by a recently
described procedure (Müller et al., 2007a, 2007b).
In order to perform spatial normalization to a common space
(Brett et al., 2002) a study-speciﬁc b0-template and an FA-template
were created (Müller et al., 2007a; Müller et al., 2009; Unrath et al.,
2010). Normalization to an FA-template was further included into
the process of normalization because a non-afﬁne registration to an
FA-template has the advantage of providingmore contrast in comparison
to b0-images (Smith et al., 2006).
In a next step a non-linear normalization of the DTI data sets was
performed by minimizing the squared differences of regional intensi-
ties between the normalized FA-maps and the FA-template (follow-
ing the basic ideas of Ashburner and Friston (1999)).Table 1
Acquisition parameters of the 4 different centers. N of (b=1000 s/mm2) reﬂects the numb





A Philips Achieva 3.0 T SENSE-8 55 2.0 11
B Siemens TIMTRIO 3.0 T 8 channel 65 2.0 9
C Siemens Verio 3.0 T 8 channel 76 2.0 12
D Siemens Allegra 3.0 T Head-coil 52 2.2 9The whole normalization process was iterative. Scanner- and se-
quence speciﬁc b0- and FA-templates were created by arithmetically
averaging data sets of all participants for each site after linear trans-
formation according to manually set landmarks. After initial normal-
ization, templates were created during an iterative step to further
optimize the normalization matrices. This process was repeated
until the correlation was >0.7 between the individual FA-maps and
the FA-template, which was achieved by one iteration.
According to standard methods (Basser and Jones, 2002), the
second-rank diffusion tensor⇀⇀D , the eigenvalues (λ1,λ2,λ3), the ei-
genvectors (⇀ν1;⇀ν2;⇀ν3), and the FA for quantiﬁcation of the dif-
fusion anisotropy were calculated after normalization of individual
DTI data sets.
Since ﬁlter size may inﬂuence the results of the DTI data analysis
(Henley et al., 2010; Jones et al., 2005), the ideal adjustment of the
smoothing kernel requires application of the matched ﬁlter theorem
which states that the ﬁlter size should be tailored to the size of the
expected difference (Rosenfeld and Kak, 1982). Based on results
from previous studies that had already tested several ﬁlter sizes be-
tween 6 and 10 mm full width at half maximum (FWHM) in DTI anal-
ysis of FA and mean diffusivity values (Müller et al., 2012; Unrath et
al., 2010) and informed by previous voxel-based morphometry stud-
ies of T1-weighted data (Henley et al., 2010; Kassubek et al., 2004) we
used an estimated Gaussian ﬁlter size of 8 mm FWHM for smoothing
to balance the trade-off between sensitivity and speciﬁcity.
2.3. Coefﬁcients of variation (CV)
The CV is deﬁned as the ratio of the standard deviation of the mea-
surements divided by themeanmultiplied by 100. It is an intuitive es-
timate of measurement variance expressed as relative percentage
regardless of the absolute measurement value and reﬂects the inverse
of the signal-to-noise ratio. In previous studies on DTI test–retest re-
liability the CV is a frequently reported statistical measure (Vollmar et
al., 2010). Since testing whether or not differences between centers
are beyond chance imposes a comparable reliability problem, we de-
cided to use this measure for reliability tests in controls. CV values of
FA data were computed in different ROIs. Using previous reference
studies (Douaud et al., 2009; Rosas et al., 2006) these a priori deﬁned
anatomical ROIs were located in the basal ganglia, the external cap-
sule, the thalamus, the internal capsule, and the corpus callosum
(Fig. 2). CVs were averaged per ROI and subject and were then tested
on signiﬁcant center effects using a one-way analysis of variance with













2×112 2.0×2.0 42 1 8077/56
6×128 2.0×2.0 41 7 7600/84
8×128 2.0×2.0 42 7 7600/84
6×128 2.2×2.2 47 1 7600/85
Fig. 2. Coefﬁcients of variation (corrected for age) for different ROIs calculated for control subjects (CO) from each center.
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For each ROI used in the between-center comparisons of the CVs,
averages of FA values were computed for each individual and entered
into an analysis of variance with main factors group (2 levels: con-
trols, patients) and center (4 levels). In this analysis, the
group-by-center interaction is particularly informative because it per-
mits inference whether or not group differences of the mean FA
values would signiﬁcantly differ between centers.
2.5. Whole brain-based statistical analyses
Voxel-wise statistical comparison between HD and control subjects
was performed by Student's t-tests implemented in the TIFT software
(Müller et al., 2007a) to infer signiﬁcant differences of FAmaps between
both groups. FA values below 0.2 were not considered for calculation
since cortical gray matter may show FA values of up to 0.2
(Kunimatsu et al., 2004). Correction for multiple comparisons used
the false-discovery-rate (FDR) algorithm at a nominal level of pb0.05
(Genovese et al., 2002). To further reduce alpha error a spatial correla-
tion algorithmwas used for eliminating isolated voxels or small isolated
groups of voxels. This has led to a threshold cluster size of 512 contigu-
ously signiﬁcant voxels.
3. Results
The Results section follows the outline of the suggested three-step
procedure by ﬁrst analyzing CV in control participants and then analyz-
ing differences of FA values between HD and control participants. These
two steps were based on pre-deﬁned regions of interest. In the third
step, a voxel-wise analysis of FA maps is performed, to see whether
the overall pattern of impairments matches the expected one (Fig. 1).
3.1. Step 1: a) age and sex distribution in controls
To control for subject factors (see Fig. 1) as a potential source of vari-
ability in control participants we ﬁrst examined the distribution ofdemographic variables of age and sex between sites. An analysis of vari-
ance (ANOVA) on age showed a signiﬁcant center effect (F(3,36)=3.99,
p=0.02). Post-hocNewman–Keuls tests (nominal alpha level of pb0.05)
revealed that control participants at center C were signiﬁcantly older
than control participants at center D (p=0.01). No other pairwise
comparison was signiﬁcant. Distribution of sex (chi2=2.02; degrees of
freedom (d.f.)=3; p=0.57) did not differ between study centers
(center-speciﬁc demographic details are summarized in Table 2).
3.2. Step 1: b) testing on center effects in controls
Due to the results above, age was added as a covariate to the ANOVA
when testing for center effects on CV. One-way ANOVAs with age as a
covariate showed no signiﬁcant differences of CV between centers for
the ﬁve predeﬁned ROIs (highest F-value: F(3,35) 1.73, p=0.18; exter-
nal capsule). Results are shown in Fig. 2 (F-values and associated
p-values are shown above the bars; d.f. was 3.35 for each analysis).
One-way ANOVAs without age as covariate did not change the pattern
of results (highest F-value: F(3,36)=2.47; p=0.08; external capsule).
At one speciﬁc site it had become necessary to scan subjects with
shorter echo times (TE) than at the three other sites (see Table 1).
Since diffusion quantiﬁcation may change with TE (e.g. Qin et al.,
2009) we used TE as a second covariate. With this, the overall pattern
of insigniﬁcant center effects remained stable for each ROI (highest
F-value: F(3,34)=2.03; p=0.13; external capsule).
Finally, the same analysis was repeated but now on FA values.
Center effects were again not signiﬁcant for all ROIs (basal ganglia:
F(3,34)=0.35; p=0.79; external capsule: F(3,34)=1.94; p=0.14;
thalamus: F(3,34)=1.45; p=0.25; internal capsule: F(3,34)=1.74;
p=0.18; corpus callosum: F(3,34)=1.54; p=0.22).
3.3. Step 2: a) age and sex distribution in patients and controls
As for the CV statistics, the demographic variables age and sex dis-
tribution were tested for signiﬁcant group-by-center interactions by
two separate analyses. An ANOVA with age as the dependent variable
did not show a signiﬁcant effect for group (F(1,93)=2.34; p=0.13)
Table 3
Results of analyses of variance on ROI averaged FA values with and without the covariate sex; the anatomical location of the ﬁve different ROIs is depicted in Fig. 2; the degrees of
freedom (d.f.) of each F-statistic is given in brackets. The listed values were obtained for differences between the HD and the control group.
In the presence of the covariate sex No covariates
Group Group-by-center Group Group-by-center
F(1,92) p F(3,92) p F(1,93) p F(3,93) p
Basal ganglia 28.22 b0.001 1.54 0.209 27.56 b0.001 2.42 0.071
External capsule 11.26 0.001 0.45 0.717 11.40 0.001 0.49 0.693
Thalamic region 19.14 b0.001 0.84 0.475 19.38 b0.001 1.27 0.288
Internal capsule 18.56 b0.001 0.17 0.915 18.72 b0.001 0.16 0.922
Corpus callosum 11.68 0.001 0.31 0.816 11.75 0.001 0.29 0.835
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thereof (F(3,93)=1.89; p=0.14). Sex distribution, however, differed
across centers (chi2=16.06; d.f.=7; p=0.03), in that centers A, B
and D included unequal numbers of male and female HD participants
(Table 2).3.4. Step 2: b) testing on center effects of FA differences between patients
and controls
Statistical tests for signiﬁcant group-by-center interactions were
computed with FA as the dependent variable and sex as covariate.
For each of the ﬁve ROIs we found a signiﬁcant effect of group
(Table 3) indicating differences in mean FA values between patients
and controls for each region when averaging across centers. The
group-by-center interactions (Table 3) were far from signiﬁcance
for all ROIs, supporting that group differences between patients and
controls were not systematically inﬂuenced by being collected at a
speciﬁc center (see Fig. 3). Removing the covariate sex from the anal-
ysis did not change the pattern of results (see Table 3 and Fig. 3 for
details).3.5. Step 3: voxel-wise whole brain analysis of group differences
Whole brain-based spatial statistics for pooled FA data showed
patterns of signiﬁcant group differences encompassing all ﬁve ROIs
(Fig. 4). Basal ganglia FA was signiﬁcantly increased in HD patients
compared to controls, whereas decreases of FA were found in theFig. 3. FA differences (corrected for inﬂuences of sex) from controls (CO) and patients with
differences in different ROIs for data pooled across centers.thalamic region, the internal and external capsules and the corpus
callosum in HD patients.
4. Discussion
In order to comply with the requirements for increased statistical
power and consistency of results in clinical imaging studies, it is
necessary to scan increasingly larger sample sizes. This demands
data to be collected across multiple study sites, since one single cen-
ter is unlikely to be able to acquire such sample sizes in a reasonable
timeframe. Ideally, measured diffusion metrics should be identical
across different MR scanners after their calibration. In reality, howev-
er, differences between scanning parameters at different sites and
with various scanner types can inﬂuence the homogeneity of diffusion-
derived dependent variables. Further sources of variation include envi-
ronmental noise and inter-site and inter-subject variability. Also, since
one single voxel covers multiple axon bundles, slight differences in posi-
tioningmay result in averaging different FA values of the same voxel be-
cause even a slight shift in the voxel position could lead to a different
coverage of axon bundles. This cannot be completely compensated by
spatial smoothing of the FA maps.
The variability of diffusion data has already been extensively stud-
ied in previous research (Pagani et al., 2010; Teipel et al., 2011;
Vollmar et al., 2010;Walker et al., 2012). Nevertheless, a speciﬁc mul-
ticenter study may not have the resources to repeatedly scan a large
number of participants at each site and will have to develop a proce-
dure to overcome potential problems associated with between-site
variability within practical and ﬁnancial constraints unique to thatHuntington's disease (HD) in different ROIs for different centers. Lower panel right: FA
Fig. 4. Whole-brain spatial statistic demonstrating clusters of signiﬁcant FA differences between patients with HD and controls encompassing those predeﬁned ROIs used for the
calculation of preceding test statistics (compare Fig. 2). Hot colors indicate FA decrease from controls to HD, and cold colors indicate FA increase.
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ternative approach to evaluate the feasibility of pooling multicenter
data in a valid and robust fashion.
Within the framework of a three-step testing procedure we ob-
served that in control participants CVs calculated in different a priori
selected ROIs did not signiﬁcantly differ between study sites. Al-
though the speciﬁc contribution of any individual source of variation
cannot be detected by this approach, the consistency of this measure
across centers suggests that a systematic bias due to one or more cen-
ters is unlikely. Especially when controlling for inﬂuences of control
participants' age all F-values in the present analyses of center effects
on CV data were clearly below the critical threshold of F(3,35)=
2.25 which would have indicated effects at a level of pb0.10, hereby
also ruling out the idea that keeping the null-hypothesis may have
been an issue of insufﬁcient power.
In a next step we tested whether ROI based group differences be-
tween patients and controls would differ between centers. Again, all
F-values of the group-by-center interactions of interest were clearly
below the critical value of F(3,91)=2.15 (associated p=0.10) when
controlling for additional effects of unbalanced sex distributions across
groups and centers. In the absence of this covariate only one (basal
ganglia; Table 3) of the ﬁve analyses of variances showed an F-value
above the critical threshold of F(3,93)=2.14 (p=0.10) which however
was still beyond signiﬁcance, thus supporting the conclusion that none
of the study centers had contributed systematically biased differences.
The results of our analysis demonstrate that multicenter pooling
of DTI data can be performed in a valid manner. The resulting
voxelwise pattern of FA group differences between patients and con-
trols showed a high consistency with previous reports performed at
single centers (Douaud et al., 2009; Rosas et al., 2006; Weaver et al.,
2009) and also encompassed all ROIs from which previous test statis-
tics had been derived. Rosas et al. (2006) compared FA maps of HD
subjects against controls on a single center level, and they found de-
creases in the internal and external capsules, the corpus callosum
and the thalamic region, whereas an increase was found in the basal
ganglia. This increase in the basal ganglia appears to be a main feature
of HD pathology probably reﬂecting a decline of medium spiny neu-
rons. In healthy participants, the complex neural connectivity of the
basal ganglia results in a net diffusion with low FA values. However,
the disease related atrophy of those medium spiny neurons which
have a distinct orientation results in a net increase of FA values for
the basal ganglia because other neurons with a different orientation
remain unaffected. Therefore, an increase of directionality of water
molecules' diffusion within the basal ganglia most likely indicates a
disturbance in this region (Douaud et al., 2009). Anatomical struc-
tures affected by the disease process in HD were also identiﬁed by
structural MRI studies (for review see Bohanna et al. (2008) and
Klöppel et al. (2009)) as well as by functional MRI studies (for review
see Albin et al. (1995)). The identiﬁed key structures were again thebasal ganglia, the thalamus, the external and internal capsules as
well as the corpus callosum. Accordingly, the clinical symptoms in
HD most likely result from an abnormal functioning of the basal-
ganglia-thalamo-cortical circuitry that may originate from striatal de-
generation (Albin et al., 1995; Douaud et al., 2009; Rosas et al., 2006).
5. Conclusion
Patterns of changes in fractional anisotropy associated with early
HD need to be reproduced at larger scales in order to improve reliabil-
ity and to meet the requirements of clinical trials, which imposes the
necessity of multicenter studies. In the present study we present a
new approach for assessing feasibility and validity of pooling DTI
data from different centers if time or cost limitations do not permit
scanning of a reference sample at each study site. This study may
serve as a reference for future multicenter trials employing MRI to
measure disease-speciﬁc progression independent of site speciﬁc
conditions. Another technical application of this methodological
framework may be the interim quality control of DTI data during an
ongoing multicenter imaging trial.
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